Rational, Trial Design, and Rational, Trial Design, and Results of the ADAGIO Delayed Results of the ADAGIO Delayed Start Trial Start Trial C. Warren Olanow, MD, FRCPC C. Warren Olanow, MD, FRCPC Henry P. and Georgette Goldschmidt Professor Henry P. and Georgette Goldschmidt Professor Chairman Emeritus, Department of Neurology Chairman Emeritus, Department of Neurology Professor, Department of Neuroscience Professor, Department of Neuroscience Director, Robert and John M. Bendheim Parkinson's Disease Center Director, Robert and John M. Bendheim Parkinson's Disease Center Mount Sinai School of Medicine Mount Sinai School of Medicine New York, New York New York, New York Mechanisms ● Mortality ● Mechanisms ● Mortality ● Therapeutics Therapeutics
Rational, Trial Design, and Results of the ADAGIO Delayed Start Trial
Dec 30, 2015
Mechanisms ● Mortality ● Therapeutics. Rational, Trial Design, and Results of the ADAGIO Delayed Start Trial. - PowerPoint PPT Presentation
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Rational, Trial Design, and Results of the Rational, Trial Design, and Results of the ADAGIO Delayed Start TrialADAGIO Delayed Start Trial
C. Warren Olanow, MD, FRCPCC. Warren Olanow, MD, FRCPCHenry P. and Georgette Goldschmidt ProfessorHenry P. and Georgette Goldschmidt ProfessorChairman Emeritus, Department of NeurologyChairman Emeritus, Department of Neurology
Professor, Department of NeuroscienceProfessor, Department of NeuroscienceDirector, Robert and John M. Bendheim Parkinson's Disease CenterDirector, Robert and John M. Bendheim Parkinson's Disease Center
Mount Sinai School of MedicineMount Sinai School of MedicineNew York, New YorkNew York, New York
Mechanisms ● Mortality ● TherapeuticsMechanisms ● Mortality ● Therapeutics
Schematic Illustration of the Three Schematic Illustration of the Three Primary End Points of the StudyPrimary End Points of the Study
Olanow CW, et al. N Engl J Med 2009;361:1268-78.Olanow CW, et al. N Engl J Med 2009;361:1268-78.
Randomization and Treatment Randomization and Treatment of the Study Subjectsof the Study Subjects
Olanow CW, et al. N Engl J Med 2009;361:1268-78.Olanow CW, et al. N Engl J Med 2009;361:1268-78.
Baseline CharacteristicsBaseline Characteristics
Olanow CW, et al. N Engl J Med 2009;361:1268-78.Olanow CW, et al. N Engl J Med 2009;361:1268-78.
Results for Primary and Results for Primary and Secondary CharacteristicsSecondary Characteristics
Olanow CW, et al. N Engl J Med 2009;361:1268-78.Olanow CW, et al. N Engl J Med 2009;361:1268-78.
Changes in Scores on the Unified Changes in Scores on the Unified Parkinson’s Disease Rating ScaleParkinson’s Disease Rating Scale
Olanow CW, et al. N Engl J Med 2009;361:1268-78.Olanow CW, et al. N Engl J Med 2009;361:1268-78.
Adverse EventsAdverse EventsAccording to Treatment GroupAccording to Treatment Group
Olanow CW, et al. N Engl J Med 2009;361:1268-78.Olanow CW, et al. N Engl J Med 2009;361:1268-78.
Adverse EventsAdverse EventsAccording to Treatment Group (cont)According to Treatment Group (cont)
Olanow CW, et al. N Engl J Med 2009;361:1268-78.Olanow CW, et al. N Engl J Med 2009;361:1268-78.
Adverse EventsAdverse EventsAccording to Treatment Group (cont)According to Treatment Group (cont)
Olanow CW, et al. N Engl J Med 2009;361:1268-78.Olanow CW, et al. N Engl J Med 2009;361:1268-78.
Related Documents
